Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

References

• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. doi:10.1016/j.cell.2015.03.030.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–55. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Moynihan KD, Irvine DJ. Roles for innate immunity in combination immunotherapies. Cancer Res. 2017;77(19):5215–21. doi:10.1158/0008-5472.CAN-17-1340.
   PubMed Web of Science ®Google Scholar
• Ho CCM, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Özkan E, Mori Y, Weissman IL, Garcia KC. “Velcro” engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem. 2015;290(20):12650–63. doi:10.1074/jbc.M115.648220.
   PubMed Web of Science ®Google Scholar
• Barclay AN, Van Den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50. doi:10.1146/annurev-immunol-032713-120142.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci. 2012;109(17):6662–67. doi:10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Lange J, Skaletsky H, van Daalen SKM, Embry SL, Korver CM, Brown LG, Oates RD, Silber S, Repping S, Page DC. Isodicentric Y chromosomes and sex disorders as byproducts of homologous recombination that maintains palindromes. Cell. 2009;138(5):855–69. doi:10.1016/j.cell.2009.07.042.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016;113(19):E2646–E2654. doi:10.1073/pnas.1604268113.
   PubMed Web of Science ®Google Scholar
• Ge C, Du J, Zhao, L, Wang L, Liu Y, Li D, Yang Y, Zhou R, Zhao Y, Chai Z, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A. 2011;108(41):16968–7. doi:10.1073/pnas.1105270108.
   PubMed Web of Science ®Google Scholar
• Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci. 2013;110(27):11103–08. doi:10.1073/pnas.1305569110.
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu Y-X, Xu MM. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209–15. doi:10.1038/nm.3931.
   PubMed Web of Science ®Google Scholar
• Kauder SE, Kuo TC, Harrabi O, Chen A, Sangalang E, Doyle L, Rocha SS, Bollini S, Han B, Sim J, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018;13(8):e0201832. doi:10.1371/journal.pone.0201832.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2017;31(5):1253–54. doi:10.1038/leu.2017.14.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, Özkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341(6141):88–91. doi:10.1126/science.1238856.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713. doi:10.1016/j.cell.2010.07.044.
   PubMed Web of Science ®Google Scholar
• Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer J-P, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, et al.; Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017;114(49):E10578–E10585. doi:10.1073/pnas.1710877114.
   PubMed Web of Science ®Google Scholar
• Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer. 2017;76:100–09. doi:10.1016/j.ejca.2017.02.013.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–21. doi:10.1056/NEJMoa1807315.
   PubMed Web of Science ®Google Scholar
• Lakhani N, LoRusso P, Chow LQ, Bang Y, Gainor J, Lee J, Chung H, Lee K, Hodi S, Fanning P, et al. A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy [abstract]. Proccedings of the 33rd Annual Meeting of the Society for Immunotherapy of Cancer; 2018 Nov 7-11; Washington, DC, p Abstract nr P335.
   Google Scholar
• Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, et al. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017;114(38):10184–89. doi:10.1073/pnas.1710776114.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9):e0137345. doi:10.1371/journal.pone.0137345.
   PubMed Web of Science ®Google Scholar
• Vernet M-A, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, et al. Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight. 2017;2(6):e89140. doi:10.1172/jci.insight.88864.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Szilagyi K, Barclay NA, van Den Berg TK. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145–64. doi:10.1111/imr.2017.276.issue-1.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Prasolava TK, Wang JCY, Mortin-Toth SM, Khalouei S, Gan OI, Dick JE, Danska JS. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8(12):1313–23. doi:10.1038/ni1527.
   PubMed Web of Science ®Google Scholar
• Treffers LW, Zhao XW, van der Heijden J, Nagelkerke SQ, van Rees DJ, Gonzalez P, Geissler J, Verkuijlen P, van Houdt M, de Boer M, et al. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells. Eur J Immunol. 2018;48(2):344–54. doi:10.1002/eji.201747215.
   PubMed Web of Science ®Google Scholar
• Sudmant PH, Rausch T, Gardner EJ, Handsaker RE, Abyzov A, Huddleston J, Zhang Y, Ye K, Jun G, Hsi-Yang Fritz M, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526(7571):75–81. doi:10.1038/nature15394.
   PubMed Web of Science ®Google Scholar
• O’Leary MA, Bloch JI, Flynn JJ, Gaudin TJ, Giallombardo A, Giannini NP, Goldberg SL, Kraatz BP, Luo Z-X, Meng J, et al. The placental mammal ancestor and the post-K-Pg radiation of placentals. Science. 2013;339(6120):662–67. doi:10.1126/science.1229237.
   PubMed Web of Science ®Google Scholar
• Dodgson JB, Delany ME, Cheng HH. Poultry genome sequences: progress and outstanding challenges. Cytogenet Genome Res. 2011;134(1):19–26. doi:10.1159/000324413.
   PubMed Web of Science ®Google Scholar
• Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, et al. Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs. 2016;8(6):999–1009. doi:10.1080/19420862.2016.1196521.
   PubMed Web of Science ®Google Scholar
• Ching KH, Collarini EJ, Abdiche YN, Bedinger D, Pedersen D, Izquierdo S, Harriman R, Zhu L, Etches RJ, van de Lavoir M-C, et al. Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets. MAbs. 2018;10(1):71–80. doi:10.1080/19420862.2017.1386825.
   PubMed Web of Science ®Google Scholar
• Schusser B, Collarini EJ, Pedersen D, Yi H, Ching K, Izquierdo S, Thoma T, Lettmann S, Kaspers B, Etches RJ, et al. Expression of heavy chain-only antibodies can support B-cell development in light chain knockout chickens. Eur J Immunol. 2016;46(9):2137–48. doi:10.1002/eji.201546171.
   PubMed Web of Science ®Google Scholar
• Mettler Izquierdo S, Varela S, Park M, Collarini EJ, Lu D, Pramanick S, Rucker J, Lopalco L, Etches R, Harriman W. High-efficiency antibody discovery achieved with multiplexed microscopy. Microscopy. 2016;65(4):341–52. doi:10.1093/jmicro/dfw014.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung AY, Ni I, Stone D, Miles A, Morishige W, Rossi A, Strop P, Mantis NJ. Antibodies targeting closely adjacent or minimally overlapping epitopes can displace one another. PLoS One. 2017;12(1):e0169535. doi:10.1371/journal.pone.0169535.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Miles A, Eckman J, Foletti D, Van Blarcom TJ, Yeung YA, Pons J, Rajpal A, Dübel S. High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity. PLoS One. 2014;9(3):e92451. doi:10.1371/journal.pone.0092451.
   PubMed Web of Science ®Google Scholar
• Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell. 2008;31(2):266–77. doi:10.1016/j.molcel.2008.05.026.
   PubMed Web of Science ®Google Scholar
• Spangler JB, Tomala J, Luca V, Jude K, Dong S, Ring A, Votavova P, Pepper M, Kovar M, Garcia K. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity. 2015;42(5):815–25. doi:10.1016/j.immuni.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292(9):3900–08. doi:10.1074/jbc.M116.767749.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR. J Biol Chem. 2001;276(9):6591–604. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Poirier N, Mary C, Vanhove B, Gauttier V, Thepenier V, Pengam S. International Patent Publication WO2017178653A3. New anti-SIRPa antibodies and their therapeutic applications. 2017.
   Google Scholar
• Hayashi A, Ohnishi H, Okazawa H, Nakazawa S, Ikeda H, Motegi S-I, Aoki N, Kimura S, Mikuni M, Matozaki T. Positive regulation of phagocytosis by SIRPβ and its signaling mechanism in macrophages. J Biol Chem. 2004;279(28):29450–60. doi:10.1074/jbc.M400950200.
   PubMed Web of Science ®Google Scholar
• Murata Y, Tanaka D, Hazama D, Yanagita T, Saito Y, Kotani T, Oldenborg P-A, Matozaki T. Anti-human SIRPα antibody is a new tool for cancer immunotherapy. Cancer Sci. 2018;109(5):1300–08. doi:10.1111/cas.2018.109.issue-5.
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Page KM, Fish S, Brennan A, Cook TA, Moreira K, Zhang M, Jesson M, Marquette K, Agostinelli R, et al. Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Immunology. 2014;143(3):416–17. doi:10.1111/imm.12319.
   PubMed Web of Science ®Google Scholar
• Iwamoto C, Takenaka K, Urata S, Yamauchi T, Shima T, Kuriyama T, Daitoku S, Saito Y, Miyamoto T, Iwasaki H, et al. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. Exp Hematol. 2014;42(3):163–171.e1. doi:10.1016/j.exphem.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre M-L, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PWHI, Bluestone JA, et al. In Vitro Characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200(1):16–26. doi:10.1006/cimm.2000.1617.
   PubMed Web of Science ®Google Scholar
• Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG. Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem. 2006;358(2):281–88. doi:10.1016/j.ab.2006.08.005.
   PubMed Web of Science ®Google Scholar
• Hatherley D, Lea SM, Johnson S, Barclay AN. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47. J Biol Chem. 2014;289(14):10024–28. doi:10.1074/jbc.M114.550558.
   PubMed Web of Science ®Google Scholar
• Shrake A, Rupley JA. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. J Mol Biol. 1973;79(2):351–71. doi:10.1016/0022-2836(73)90011-9.
   PubMed Web of Science ®Google Scholar
• Hasel W, Hendrickson TF, Still WC. A rapid approximation to the solvent accessible surface areas of atoms. Tetrahedron Comput Methodol. 1988;1(2):103–16. doi:10.1016/0898-5529(88)90015-2.
   Google Scholar
• Hatherley D, Harlos K, Dunlop DC, Stuart DI, Barclay AN. The Structure of the macrophage signal regulatory protein α (SIRPα) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors. J Biol Chem. 2007;282(19):14567–75. doi:10.1074/jbc.M611511200.
   PubMed Web of Science ®Google Scholar